C-terminal octapeptide of cholecystokinin decreases food intake in obese men

Physiol Behav. 1982 Oct;29(4):627-30. doi: 10.1016/0031-9384(82)90230-x.


Six of eight obese men ate significantly less food during an intravenous infusion of the C-terminal octapeptide of cholecystokinin (CCK-8, 4 ng . kg-1 . min-1) than during a saline infusion in a double blind experimental paradigm. Subjects stopped eating sooner during CCK-8. CCK-8 did not change the rate of eating. No overt side effects were reported or observed. This is the first report of the satiety effect of CCK-8 in obese humans and it suggests that the therapeutic potential of CCK-8 for the treatment of obesity deserves investigation.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Body Weight / drug effects*
  • Cholecystokinin / therapeutic use*
  • Eating / drug effects*
  • Energy Intake / drug effects
  • Humans
  • Male
  • Obesity / drug therapy*
  • Peptide Fragments / therapeutic use*
  • Sincalide


  • Peptide Fragments
  • Cholecystokinin
  • Sincalide